Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors

Transplantation

Volumn 64, Issue 11, 1997, Pages 1614-1617

  Seu, Philip ^a   Winston, Drew J ^a,b   Holt, Curtis D ^a   Kaldas, Fady ^a   Busuttil, Ronald W ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; OKT 3; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEPATITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; NEUTROPENIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GANCICLOVIR; HUMANS; INFANT; LIVER TRANSPLANTATION; MIDDLE AGED;

EID: 0031441891     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712150-00022     Document Type: Article

References (14)

1. Winston DJ, Emmanouilides C, Busuttil RW. State-of-the-art clinical article: infection in liver transplant recipients. Clin Infect Dis 1995; 21: 1077.
2. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
3. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
4. Busuttil RW, Shaked A, Millis JM, et al. One thousand liver transplants: the lessons learned. Ann Surg 1994; 219: 490.
5. Emmanouilides C, Holt CD, Winston DJ. Infections after liver transplantation. In: Busuttil RW, Klintmalm GB, eds. Transplantation of the liver. Philadelphia: Saunders, 1996: 633.
6. Saliba F, Arulnaden JL, Gugenheim J, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 1989; 21: 2260.
7. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin for prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119: 984.
8. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779.
9. Manez R, Kusne S, Rinaldo C, et al. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J Infect Dis 1996; 1072.
10. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996; 61: 1659.
11. Hibberd PJ, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995; 123: 18.
12. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168: 332.
13. Slavin MA, Bindra RR, Gleaves CA, Pettinger MB, Bowden RA. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 37: 1360.
14. Pescovitz M, Gane E, Saliba F, et al. Efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus (CMV) disease in liver transplant recipients. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996: 163.